

# Chia-Chyi Liu

## List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/5390231/publications.pdf](https://exaly.com/author-pdf/5390231/publications.pdf)

Version: 2025-02-01

45

PR articles

1,521

PR citations

287960

21

PR h-index

272640

38

g-index

47

documents

1695

doc citations

299426

22

h-index

1285

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Enhanced production of recombinant coxsackievirus A16 using a serum-free HEK293A suspension culture system for bivalent enterovirus vaccine development. <i>Vaccine: X</i> , 2024, 20, 100559.	1.8	0
2	Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system. <i>Virus Research</i> , 2023, 329, 199101.	2.6	3
3	The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 1121-1128.	3.2	1
4	Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 27-39.	4.5	25
5	Separation and purification of highly infectious enterovirus A71 particles using a strong anion-exchange column. <i>Journal of Chromatography A</i> , 2022, 1680, 463427.	3.7	3
6	Glycan masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development. <i>Biotechnology and Bioengineering</i> , 2019, 116, 598-609.	3.9	20
7	Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development. <i>Vaccine</i> , 2019, 37, 6933-6941.	3.2	11
8	Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development. <i>Antiviral Research</i> , 2019, 164, 12-22.	3.8	10
9	Mutations in VP1 and 5' UTR affect enterovirus 71 virulence. <i>Scientific Reports</i> , 2018, 8, .	3.5	20
10	Enhancing enterovirus A71 vaccine production yield by microcarrier perfusion bioreactor culture. <i>Vaccine</i> , 2018, 36, 3134-3139.	3.2	14
11	Maternal immunization with a recombinant adenovirus-expressing fusion protein protects neonatal cotton rats from respiratory syncytia virus infection by transferring antibodies via breast milk and placenta. <i>Virology</i> , 2018, 521, 181-189.	2.3	10
12	Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. <i>Expert Review of Vaccines</i> , 2018, 17, 819-831.	4.1	49
13	Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology. <i>Antiviral Research</i> , 2016, 132, 225-232.	3.8	13
14	Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. <i>Antiviral Research</i> , 2016, 129, 58-66.	3.8	39
15	Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design. <i>Antiviral Research</i> , 2016, 133, 110-118.	3.8	8
16	Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture. <i>Antiviral Research</i> , 2016, 130, 27-35.	3.8	6
17	Recombinant Adeno-Vaccine Expressing Enterovirus 71-Like Particles against Hand, Foot, and Mouth Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003692.	3.1	24
18	Review of Enterovirus 71 Vaccines. <i>Clinical Infectious Diseases</i> , 2015, 60, 797-803.	5.4	129

#	ARTICLE	IF	PR CITATIONS
19	Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques. <i>PLoS ONE</i> , 2014, 9, e106756.	2.4	8
20	Toll-Like Receptor 9-Mediated Protection of Enterovirus 71 Infection in Mice Is Due to the Release of Danger-Associated Molecular Patterns. <i>Journal of Virology</i> , 2014, 88, 11658-11670.	3.7	41
21	Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems. <i>BioMed Research International</i> , 2014, 2014, 1-8.	2.5	18
22	Delivery of Human EV71 Receptors by Adeno-Associated Virus Increases EV71 Infection-Induced Local Inflammation in Adult Mice. <i>BioMed Research International</i> , 2014, 2014, 1-12.	2.5	3
23	Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. <i>Vaccine</i> , 2014, 32, 6177-6182.	3.2	68
24	A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. <i>Vaccine</i> , 2013, 31, 2471-2476.	3.2	73
25	Caveolar Endocytosis Is Required for Human PSGL-1-Mediated Enterovirus 71 Infection. <i>Journal of Virology</i> , 2013, 87, 9064-9076.	3.7	49
26	Monoclonal Antibodies for Diagnosis of Enterovirus 71. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2013, 32, 386-394.	1.0	9
27	Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2378-2385.	3.2	7
28	Human SCARB2 Transgenic Mice as an Infectious Animal Model for Enterovirus 71. <i>PLoS ONE</i> , 2013, 8, e57591.	2.4	96
29	Protective Efficacy of VP1-Specific Neutralizing Antibody Associated with a Reduction of Viral Load and Pro-Inflammatory Cytokines in Human SCARB2-Transgenic Mice. <i>PLoS ONE</i> , 2013, 8, e69858.	2.4	19
30	Heat Shock protein 90: Role in Enterovirus 71 Entry and Assembly and Potential Target for Therapy. <i>PLoS ONE</i> , 2013, 8, e77133.	2.4	65
31	Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers. <i>PLoS ONE</i> , 2013, 8, e79783.	2.4	81
32	Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.5	30
33	Selection and characterization of vaccine strain for Enterovirus 71 vaccine development. <i>Vaccine</i> , 2012, 30, 703-711.	3.2	59
34	Human SCARB2-Mediated Entry and Endocytosis of EV71. <i>PLoS ONE</i> , 2012, 7, e30507.	2.4	70
35	Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates. <i>PLoS ONE</i> , 2012, 7, e34834.	2.4	56
36	Immunological and Biochemical Characterization of Coxsackie Virus A16 Viral Particles. <i>PLoS ONE</i> , 2012, 7, e49973.	2.4	52

#	ARTICLE	IF	PR CITATIONS
37	Identification and characterization of a cross-neutralization epitope of Enterovirus 71. <i>Vaccine</i> , 2011, 29, 4362-4372.	3.2	169
38	Purification and Characterization of Enterovirus 71 Viral Particles Produced from Vero Cells Grown in a Serum-Free Microcarrier Bioreactor System. <i>PLoS ONE</i> , 2011, 6, e20005.	2.4	114
39	Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates. <i>Journal of Virological Methods</i> , 2011, 173, 189-195.	1.7	23
40	Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. <i>Journal of Virological Methods</i> , 2011, 176, 60-68.	1.7	23
41	High Genetic Stability of Dengue Virus Propagated in MRC-5 Cells as Compared to the Virus Propagated in Vero Cells. <i>PLoS ONE</i> , 2008, 3, e1810.	2.4	14
42	High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. <i>Vaccine</i> , 2007, 25, 19-24.	3.2	70
43	Mosquito and mammalian cells grown on microcarriers for four-serotype dengue virus production: Variations in virus titer, plaque morphology, and replication rate. <i>Biotechnology and Bioengineering</i> , 2004, 85, 482-488.	3.9	11
44	Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. <i>Vaccine</i> , 2004, 22, 3858-3864.	3.2	70
45	The use of glucose to regulate pH values of culture media and increase the production of baculovirus (BmNPV) and foreign protein (HBsAg). <i>Process Biochemistry</i> , 1999, 34, 295-301.	3.9	1